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Abstract 
Vanadate mimics, whereas phenylarsine oxide (PAt) antagonizes, the effects of insulin in rat adipocytes. Both vanadate and PAt  are 
documented inhibitors of protein-phosphotyrosine phosphatases. The relationship between the inhibition of 'inhibitory' PTPase and 
'stimulatory' PTPase has been studied here in primary rat adipocytes. Low concentrations of PAt  (IC5o = 0.6-2.0 txM) blocked the 
stimulating effects of insulin, vanadate and pervanadate on hexose uptake and glucose metabolism. Inhibition of isoproterenol-mediating 
lipolysis by vanadate and insulin was not blocked by PAt.  The activating effects of okadaic acid on hexose uptake and glucose 
metabolism, which occur at points downstream totyrosine phosphorylation, were also not blocked by PAt. Subsequent studies uggested 
that the PAt-sensitive PTPase comprises a minute fraction of the total adipocytic PTPase activity. To identify its location we applied 
procedures involving fractionations and activation of non-receptor adipocytic protein tyrosine kinase by PAt  and vanadate in cell free 
assays. We found that the 'inhibitory' PTPase is exclusively associated with the membrane fraction whereas the 'stimulatory' PTPases are 
present in both the cytosolic and plasma membrane compartments. We next searched for markers, possibly associated with PAt-depen- 
dent desensitization a d found that several proteins became phosphorylated on tyrosine moieties in the supernatant of PAt  but not in 
vanadate pretreated adipocytes. In summary, we propose the presence of a minute, plasma membrane associated PTPase in primary rat 
adipocytes, inhibition of which arrests the activation of glucose metabolism. In contrast, inhibition of all the other cellular adipose 
PTPases, ultimately activates rather than inhibits these same bioeffects. 
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1. Introduction 
Vanadate (VOW), a documented inhibitor of protein 
phosphotyrosine phosphatases (PTPases) mimics virtually 
all the biological effects of insulin in in vitro systems 
[reviewed in [1]]. Recent data suggest that these effects are 
not mediated through the insulin receptor [2-6] and that 
several vanadate ffects are mediated through a 53-kDa 
cytosolic protein tyrosine kinase (CytPTK). Activation of 
this enzyme is increased 3- to 5-fold in vanadate-treated 
Abbreviations: PAt, phenylarsine oxide; CytPTK, cytosolic protein 
tyrosine kinase; InsRTK, insulin receptor tyrosine kinase; PTPase, protein 
phosphotyrosine phosphatase; PolyGlunTyr, poly[(GluNa:Tyr)4:1]; pNPP, 
p-nitrophenylphosphate; WGA, wheat germ agglutinin; HPLC, high per- 
formance liquid chromatography; PTK, protein tyrosine kinase; PP1, 
protein phosphoserine phosphatase-1; PP2A, protein phosphoserine phos- 
phatase 2A; PTyr, phosphotyrosine; SDS-PAGE, sodium dodecyl sul- 
phate polyacrylamide gelelectrophoresis. 
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adipocytes [7,8]. This CytPTK can also be activated by 
vanadate after cell disintegration i a cell-free assay. Low 
concentrations of vanadate (ECso 2-4 ~M) could activate 
CytPTK and inhibit PTPase activity in the 40000 × g 
supernatant fraction [9]. Thus, CytPTK activation may well 
be secondary to PTPase inhibition. The exact location and 
the nature of the vanadate-sensitive PTPases have not yet 
been identified. 
In the cell-free experimental system tungstate, molyb- 
date and phenylarsine oxide (PAt)  also activated CytPTK 
[9]. All these agents are documented inhibitors of PTPases 
[10,11]. The assumption that they are insulinomimetic was 
found to be true for vanadate, tungstate and molybdate 
[12]. The exception was phenylarsine oxide. 
Phenylarsine oxide is a trivalent arsenic compound that 
can form a covalent adduct with two closely spaced pro- 
tein cysteinyl residues [13]. PAt  permeates into the cell 
interior and inhibits or inactivates PTPases [14,15]. Unlike 
the metalooxide-PTPase inhibitors which activate, PAt  
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inhibits the effects of insulin and vanadate on glucose 
transport in 3T3-L1 adipocytes [16-19] and in primary rat 
adipocytes (this study). 
Our aim here was to study in depth PAO inhibition of 
glucose transport in rat adipocytes with special emphasis 
on this paradoxical difference between PAO and the other 
PTPase inhibitors. Glucose metabolism can be activated by 
the following four alternative modes: Through the InsRTK 
in either a hormone-dependent or a hormone-independent 
fashion by pervanadate [2,20]; by activating CytPTK (with 
vanadate, tungstate and molybdate [7,8,12]), or at points 
downstream to endogenous tyrosine phosphorylation (e.g., 
with okadaic acid, [21,22]). We intend initially to map the 
site inhibited by PAO within these alternative pathways. 
We also wished to determine whether inhibition of lipoly- 
sis by insulin or vanadate which, as we previously sug- 
gested, occurs independently of endogenous (substrate) 
tyrosyl phosphorylation [6,23], is affected by PAO. Should 
the site of PAO inhibition prove to be at the level of 
tyrosine phosphorylation then we will undertake a study to 
identify it. Most studies with PAO have been performed in 
the mouse 3T3-L1 cell-line which expresses a high number 
of insulin receptors, and several quantitative and qualita- 
tive differences compared to primary rat adipocytes [24]. 
In view of this we are systematically reexamining in the 
primary fat cells various parameters affected by PAO. 
2. Materials and methods 
2.1. Materials 
D-[U-14C], D-[I-14C], D-[6-14C]glucose, o-3-O-[methyl- 
14 C]glucose and o-[ 3 H-2]glucose were purchased from New 
England Nuclear (Boston, MA). Collagenase Type I (134 
U/mg) was obtained from Worthington Biochemicals 
(Freehold, NJ). Porcine insulin was purchased from Eli 
Lilly Co. (Indianapolis, IN). Phloretin, 3-O-methyl-D-glu- 
cose, O,L-isoproterenol-HCL, phenylarsine oxide and Poly- 
[(GluNa:Tyr)4:l] (PolyGlu4Tyr) were purchased from 
Sigma Chemical Co. (St. Louis, MO). Affinity purified 
monoclonal ntibodies to phosphotyrosine w re kindly do- 
nated by Mono-Yeda (Rehovot, Israel). ECL Western blot- 
ting detection reagents and protein A horseradish peroxi- 
dase conjugate were purchased from Amersham 
(Amersham, UK). PY-20 anti-phosphotyrosine was pur- 
chased from ICN Biochemicals (Costa Mesa, CA) Krebs- 
Ringer-bicarbonate (KRB) buffer, pH 7.4, contained NaCI, 
110 mM; NaHCO 3, 25 mM; KC1, 5 mM; KH2PO 4, 1.2 
mM; CaC12, 1.3 mM; MgSO 4, 1.3 raM. All other chemi- 
cals and reagents used in this study were of analytical 
grade. 
2.2. Cell preparation and bioassays 
Rat adipocytes were prepared from fat pads of male 
Wistar rats (100-200 g) by collagenase digestion [25]. Cell 
preparations showed more than 95% viability by Trypan 
blue exclusion, at least 3 hours after digestion. All bioas- 
says were performed as described in figure legends. Glu- 
cose transport was carried out using 3-O-[methyl-tnc]glu - 
cose [26], glucose oxidation was measured by conversion 
of D-[U-14C]glucose, D-[1-14C] or D-[6-14C]glucose to 
14COz [25] and lipogenesis by the incorporation of the 
o-[3H-2]glucose into lipids according to Moody et al. [27]. 
Lipolysis was evaluated by measuring lycerol released as 
described previously [28]. 
2.3. Preparation of adipocytic fractions as a source for 
CytPTK and PTPase activity 
Fresh adipocytes were washed three times with KRB 
buffer, pH 7.4, containing 0.7% BSA, and then twice more 
with 50 mM Hepes buffer, pH 7.4, containing 1 mM 
phenylmethylsulfonylfluoride, 10 ixg/ml leupeptin and 5 
Ixg/ml aprotinin. The cells (about 10 ml of packed 
adipocytes) were homogenized with a hand Teflon homog- 
enizer and then frozen and thawed five times. The fat was 
removed and the cell homogenate was centrifuged at 
40 000 × g for 60 min. The supernatant fraction was di- 
vided into aliquots and stored at - 137°C. 
To obtain plasma membrane PTPases, the pellet was 
washed several times, dissolved in 1% Triton X-100 and 
centrifuged again at 40 000 X g. To obtain the glycoprotein 
(or receptor-like) PTPase, the Triton X-100 soluble plasma 
membranes were affinity purified on a WGA-agarose col- 
umn [29]. 
2.3.1. Protein tyrosine kinase activity measurements 
CytPTK-assay was performed in 60 ~1 of 50 mM 
Hepes buffer (pH 7.4) containing the enzyme source (1-2 
~zg, supernatant fraction) 20 mM MgSO4; 1 mM Co 2÷, 0.1 
mM ATP, the indicated concentrations of vanadate or 
PAO, and PolyGlu4Tyr (final concentration 0.33 mg/ml). 
The reaction was terminated with EDTA (40 mM) after 40 
rain. Phosphotyrosine content in PolyGlu4Tyr was quanti- 
tated by a radioimmunoassay procedure [9,30] which uti- 
lized specific monoclonal antibodies to phosphotyrosine 
(final dilution of 1 : 100 000) and ~2s I-BSA-phosphotyrosine 
conjugate. 
2.3.2. Determination of protein tyrosine phosphorylation 
in adipocytes 
The phosphotyrosine-containing proteins were deter- 
mined in aliquots (50 Ixl) of the samples by Western blot 
analyses using polyclonal rabbit anti-PTyr antibodies. The 
adipocytes were disrupted by freezing in liquid N 2 and 
lyzed with 50 mM Hepes buffer, pH 7.5, containing 1mM 
sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 
mM sodium pyrophosphate and 10 I~g/ml each of apro- 
tinin and leupeptin; fat was removed, and the cell lysate 
was fractionated into supernatant and pellet by centrifuga- 
tion (13000Xg, 4°C, 30 min). The pellet was further 
resolved in the same buffer containing 1% Triton X-100. 
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Fig. 1. Effect of phenylarsine oxide on lipogenesis mediated by insulin, vanadate and pervanadate. (A) Adipocytes (1 • 104/ml) suspended in KRB buffer 
containing 1% BSA were preincubated with 2 ~M PAO for 10 min. Lipogenesis was then carried out with D-[aH-2]glucose, final concentration 0.2 mM in 
the absence and for 1 h at 37°C in the presence of insulin (17 nM), vanadate (1 mM), or pervanadate (10 I.tM). The amount of radioactivity incorporated 
into lipids was then determined (Section 2). (B) Dose-dependent i hibition of insulin- and vanadate-stimulated lipogenesis by PAO. Cells were incubated 
for l0 min at 37°C with the indicated concentrations of PAO prior to initiating the lipogenic assay. 
Both fractions were solubilized in sample buffer [31] con- 
taining 20 mM dithiothreitol, resolved by 7.5% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE), and electrotransferred to a nitrocellulose mem- 
brane. After blocking in 10 mM Tris-HC1 buffer, pH 7.6, 
containing 150 mM NaCI and 2% BSA, the blot was 
incubated with PY20 antibodies (0.2 txg/ml) for 16 h at 
4°C, washed several times and incubated for 1 h at 22°C 
with protein-A, horseradish peroxidase conjugate, and then 
washed again. Visualization of phosphotyrosine proteins 
was achieved by enhanced chemiluminescent (ECL)-West- 
ern blotting detection system following the manufacturer's 
protocol. 
2.3.3. PTPase activity measurement 
PTPase activity measurement was estimated by the 
potency of tissue extracts (40 Ixg protein/ml) to hydrolyze 
p-nitrophenyl phosphate (pNPP). The assay (0.2 ml) con- 
sisted of pNPP (5 mM in 50 mM Hepes, pH 7.5) the 
enzyme source and the indicated concentrations of vana- 
date, or phenylarsine oxide. The extent of the hydrolysis 
was determined spectrophotometrically t 405 nm follow- 
ing 30 minutes incubation as described by Kremerskothen 
and Barnekow [32]. 
2.3.4. Protein concentration 
Protein concentration was determined by the method of 
Bradford [33]. All the assays were performed either in 
duplicate or triplicate. The data in figures and tables are 
presented as the means_ SE from at least three separate 
experiments. The Student's t-test and/or analysis of vari- 
ance was used to compare the means of separate xperi- 
ments. 
3. Results 
3.1. Effect of phenylarsine-oxide on glucose metabolism 
and hexose-transport mediated by insulin, vanadate, per- 
vanadate and okadaic acid 
Phenylarsine oxide, at low concentrations (IC50 = 0.6-2 
I~M), blocked the activating effects of insulin, vanadate 
and pervanadate onlipogenesis and glucose oxidation (Fig. 
1, Table 1). Thus, irrespective of the activating agent, PAO 
inhibited the incorporation of [1-14C] and [6-14 C]glucose 
into lipids - -  indices of enhanced glycerol-phosphate nd 
fatty acid synthesis, and the oxidation of [6-14 C]glucose 
and [1-14C]glucose to ]4CO2-  indices of glucose oxida- 
Table 1 
Effect of PAO on insulin, vanadate and pervanadate mediated lipogenesis and glucose oxidation 
Conditions Lipogenesis (nmol/h per 104 cells) Glucose oxidation (nmol/h per 104 cells) 
[ 1-14 C]glucose [6-14 C]glucose [ 1-14 C]glucose [6- ] 4 C]glucose 
Control PAO treated Control PAO treated Control PAO treated Control PAO treated 
cells cells cells cells cells cells cells cells 
basal 2.5-t-0.20 2.5+0.15 2.8+0.10 2.9+0.20 2.5+0.25 2.5+0.25 1.8-1-0.1 1.85+0.10 
insulin (17 nM) 8.0 5:0.30 2.7 + 0.20 * * 9.0 5:0.30 2.7 5:0.20 * * 11.0 5:1.0 2.6 + 0.25 * " 9.0 5:0.7 1.90 5:0.15 " * 
vanadate (1 mM) 8.0+0.30 2.65:0.14 ** 8.55:0.30 2.95:0.20 ** 9.55:0.8 2.55:0.20 ** 8.55:0.6 1.835:0.12 ** 
pervanadate (20 ~M) 9.5 5:0.35 2.55 5:0.21 * * 9.5 5:0.35 3.1 5:0.25 * * 10.5 5:1.1 2.45:0.20 * * 9.7 5:0.8 1.905:0.13 * * 
Adipocytes (2 • 104 cells/ml) were preincubated without and with PAO (2 I~M, 10 min at 37°C). Lipogenesis and glucose oxidation were continued for an 
additional hour at 37°C. P < 0.01 ( * * ), compared with control group. 
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Fig. 2. Phenylarsine oxide blocks insulin vanadate- and pervanadate-activated hexose uptake in primary rat adipose cells: Adipocytes (40% cell suspension 
in KRBH buffer containing 4% BSA were preincubated in the presence and the absence of PAO (2 I~M) for 10 rain at 37°C and then with insulin (17 nM), 
vanadate (1 mM) or pervanadate (20 IxM) for 20 min at 37°C. Aliquots (70 Ixl) were then transferred to prewarmed (37°C) tubes containing 
3-0 - [  14 C]methylglucose (47 000 cpm/nmol; final concentration, 0.1 mM). Uptake by untreated cells was measured for 15 s (basal), and by treated cells for 
3 s. The reaction was terminated by adding phloretin (final concentration, 0.1 mM), and then an aliquot was centrifuged through the silicone oil layer. In 
the control tubes the addition of phloretin preceded that of a cell suspension, and their values were subtracted accordingly. The effect of lower 
concentrations of PAO (0.2 I~M) on 3-O-methylglucose uptake is also included (column 3). 
tion via glycolysis and the pentose phosphate pathways. 
Fifty percent inhibition of lipogenesis occurred at nearly 
the same PAO concentration whether initiated by insulin, 
vanadate (Fig. 1B), or pervanadate (not shown). 
The effect of PAO on glucose metabolism may be 
attributed to its inhibiting activation of hexose influx, 
which precedes glucose metabolism and may be rate limit- 
ing [34]. Analysis of the effects of PAO on 3-O-methyl 
glucose influx, a parameter representing hexose-uptake 
independently of glucose metabolism, revealed that PAO 
alone at low concentrations somewhat stimulated hexose 
uptake (Fig. 2). At higher concentrations, PAO blocked 
stimulation of 3-O-methyl glucose transport, mediated ei- 
ther by insulin, vanadate or pervanadate (Fig. 2) Thus, 
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Fig. 3. Lack of PAO effect on okadaic acid-dependent activation of lipogenesis, glucose oxidation and hexose uptake. Adipocytes (104 cells/ml) were 
preincubated with or without 2 IxM PAO for 10 rain, and then with okadaic acid (0.25 IxM) for 40 min at 37°C. The cells were then subjected to 
lipogenesis (left), glucose oxidation (middle) or to 3-O-methyl glucose uptake (right). Lipogenesis and glucose oxidation ran for 1 h using 0.1 mM [2-3H] 
or [6-14C]glucose, respectively. Hexose uptake was performed as described in the legend to Fig. 2 Results are expressed as % of maximal response, 
obtained with 17 nM insulin. 
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Table 2 
Lack of PAO effect on lipolysis and on the antilipolytic actions of insulin and vanadate 
227 
Treatment Glycerol released % inhibition 
(nmol/3 • 105 cells per h) of lipolysis 
basal 
PAO (1 I~M) 
isoproterenol (0.08 I~M) 
isoproterenol (0.08 txM) + PAO (1 izM) 
isoproterenol + insulin. (17 nM) 
isoproterenol + insulin (17 nM)+ PAO (1 ~M) 
isoproterenol + vanadate (1 raM) 
isoproterenol + vanadate(1 raM) + PAO (1 ~M) 
10 4- 0.5 
9+0.5  
80 + 5.0 
80 + 6.0 
18 + 2.0 89 
20 + 1.0 84.5 
11 + 1.0 98.5 
10+0.8 100 
Adipocytes were incubated for 30 min at 37°C in KRB buffer containing 0.7% BSA with the indicated concentration of PAO. Lipolysis and antilipolysis 
were allowed to proceed for 1 h at 37°C. Aliquots (0.3 ml) were withdrawn for glycerol determination. 
PAO inhibition of hexose transport could explain in part 
its effect on glucose metabolism. It is rather surprising that 
the stimulating effect of low concentrations of PAO on 
hexose-transport is not similarly reflected in activation of 
glucose metabolism. 
Assuming that an essential component of the hexose 
transport system, is blocked by PAO, it should be over- 
come by activating the system beyond the PAO inhibited 
site, and/or  by significantly increasing glucose 
metabolism. Augmenting glucose metabolism may de- 
crease intracellular glucose concentration thereby increas- 
ing the diffusion gradients. Okadaic acid activates glucose 
and fat metabolism by increasing the intracellular phospho- 
rylation on Ser/Thr moieties downstream to endogenous 
tyrosine phosphorylation [21,35]. We examined whether 
OKA can (uniquely) activate hexose uptake through a 
mechanism that is not sensitive to PAO inhibition. In 
contrast to insulin, VO 3 and pV, the activating effects of 
okadaic acid on lipogenesis, glucose oxidation and in 
activating hexose uptake were not blocked significantly by 
PAO (Fig. 3). Thus, activation of glucose uptake and its 
metabolism by OKA is PAO insensitive. 
3.2. PAO does not antagonize the antilipolytic effect of 
insulin and vanadate 
The antilipolytic effects of insulin and vanadate were 
not antagonized by PAO (Table 2). Thus, the action of 
PAO appears to be restricted to inhibition of glucose 
uptake and glucose metabolism. We have suggested previ- 
ously that insulin inhibition of lipolysis requires undis- 
turbed receptor autophosphorylation, without the need for 
a subsequent substrate phosphorylation on tyrosine moi- 
eties [6,23]. The lack of PAO effect on OKA mediated 
glucose metabolism and on insulin dependent antilipolysis 
appears to indicate that PAO does not perturb the cellular 
Ser/Thr phosphorylating machinery nor does it alter In- 
sRTK-activity. Altogether the results suggest a blockage of 
an early event involving a tyrosine phosphorylation ot 
connected to receptor activation. 
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Fig. 4. Concentration-dependent inhibition of rat adipocytic PTPases by vanadate and phenylarsine oxide. Three fractions of PTPases were studied: 
supernatant PTPases (left panel), membrane (Triton soluble) PTPases (middle panel), and receptor-like (membrane glycoprotein) PTPases (right panel). 
pNPP hydrolysis was carried out in 0.2 ml of 50 mM Hepes buffer, pH 7.4, with the indicated concentrations of vanadate or PAO. 100% activity is that 
obtained in the absence of added inhibitor. 
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Fig. 5. Activation of cytosolic protein tyrosine kinase by phenylarsine oxide and vanadate following fractionation of rat adipocytes. The standard tyrosine 
kinase assay mixture (60 ~1 final volume in 50 mM Hepes buffer, pH 7.4) contained 0.1 mM ATP, 20 mM MgSO4, 1 mM Co 2+, PolyGluaTyr 0.33 
mg/ml, and was performed in the absence or the presence of vanadate (0.1 mM) or PAO (2 IJ, M). In panel A the enzyme source is the superuatant and 
broken plasma membrane mixture. In Panel B the assay is performed after precipitating the plasma-membranes by centrifugation. In panel C the enzyme 
source is the supernatant following further passage on the millipore filter EGWP (0.2 ~,M). In panel D the enzyme source is the original plasma 
membrane-superuatant mix ure in which Triton X-100 was added to a final concentration of 1%, P < 0.05 ( * ) or P < 0.01 ( * * ), compared with control. 
3.3. The PAO sensitive PTPase is a minute fraction of  the 
cellular PTPases which is exclusively located at the plasma 
membrane fraction 
In attempts to identify the PAO sensitive species, the 
PTPases of  freshly prepared adipocytes were separated 
into supernatant (40 000 X g), plasma membranes (Triton 
X-100 soluble) and glycoprotein (receptor-l ike) fractions. 
Each of  these three fractions was examined individually. 
Vanadate inhibited pNPP hydrolysis mediated by PTPases 
derived from all three fractions examined, with IC50 values 
in the range of 2 -7  IxM. In contrast, PAO showed negligi- 
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Fig. 6. (A) Appearance of phosphotyrosine containing proteins in the supernatant of phenylarsine-oxide tr ated adipocytes. Fresh adipose cells (~ 0.5 ml 
40% suspension) were treated for 20 min at 37°C, with none, vanadate (0.1 mM) and phenylarsine-oxide (2 I~M). The cells were then disrupted, and the 
supernatant fraction was mixed with sample buffer containing final concentration of 20 mM DTT. The proteins were resolved in 7.5% SDS-PAGE, 
transferred to nitrocellulose paper and immnnoblotted with antibodies to phosphotyrosine (Section 2). (B) Scanning densitometry (Molecular Dynamics 
300A Computing Densitometer, Eugene Or) of the 43 kDa protein. 
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ble inhibition of adipose PTPases at any concentration 
examined (Fig. 4). These observations suggested to us that 
unlike with vanadate, the PAO sensitive PTPase must be a 
minor fraction of the total cellular PTPase activity. An 
alternative option considered was that pNPP is an inappro- 
priate substrate to evaluate PAO-dependent inhibition of 
PTPases. This second option, however, is less likely as we 
observed that pNPP-hydrolysis mediated by testis, thymus 
or skeletal muscle-cytosolic PTPases are inhibited by PAO 
(not shown). 
We had found earlier that PAO activates CytPTK in a 
cell-free assay [[9] and this study] so we utilized this 
parameter to try to locate the PAO-sensitive PTPase (Fig. 
5). Both vanadate and PAO activate CytPTK (about 2.7- 
fold) in a cell-free system constituting the supernatant 
fraction and broken plasma membranes (Fig. 5, panel A). 
Following precipitation ofplasma membranes at40 000 × g 
centrifugation, CytPTK could still be activated by VO 3 
and by PAO although to a lesser extent (panel B). Further 
passage of the supernatant fraction on the millipore filter 
EGWP to remove the smallest (0.2 IxM) plasma membrane 
fragments, yielded a supernatant CytPTK that could still be 
activated by vanadate but not by PAO (panel C). Follow- 
ing addition of Triton X-100 (final concentration 1%) to 
the original broken plasma membrane supernatant mixture, 
CytPTK became more sensitive to vanadate activation 
(3-fold). In contrast, PAO was no longer able to activate 
the enzyme (panel D). 
Altogether these results suggest that the vanadate-sensi- 
tive PTPases are located both in plasma membranes (about 
80% of total) and the supernatant (about 20% of total, not 
shown). The PAO-sensitive PTPase comprises a minor 
fraction of the total cellular PTPase activity and is exclu- 
sively associated with the broken, intact fragments of the 
plasma membranes. Solubilization of these fragments with 
a non-ionic detergent such as Triton X-100 significantly 
increased the level of the vanadate sensitive PTPases but 
appear to inactivate the PAO sensitive nzyme. 
3.4. Proteins are phosphol~ylated on tyrosine moieties in 
the supernatant of PAO pretreated adipocytes 
In the experiments summarized in Fig. 6, adipocytes 
were pretreated with the indicated concentration f PAO or 
vanadate for 30 min at 37°C. The cells were then lyzed and 
fractionated into supernatant and plasma membrane frac- 
tions. Each fraction was examined individually for phos- 
photyrosine-containing proteins by immunoblotting with 
anti PTyr antibodies (Experimental Section). Significant 
increase in tyrosine phosphorylation is evident with respect 
to 33, 39 (doublet), 43, 53 and 55 kDa proteins in the 
supernatant fraction (Fig. 6). These proteins were not 
phosphorylated in vanadate pretreated adipocytes. Densito- 
metric analysis of the 43 kDa protein indicated a 3-fold 
increase in its intensity in the PAO-pretreated cells (Fig. 
6). In the plasma membrane fraction, no significant differ- 
ence could be detected between the PAO and the vanadate 
pretreated adipocytes, in the pattern of phosphotyrosine- 
containing proteins (not shown). 
4. Discus~on 
In this study we have found in primary adipocytes that 
PAO, a PTPase inhibitor, blocks the activating effects of 
vanadate, insulin and pV, on hexose uptake and glucose 
metabolism (Figs. 1 and 2, and Table 1). The antilipolytic 
effects of insulin and of vanadate were not affected (Table 
2). These findings, in conjunction with previous studies, 
suggest a priori that the site blocked by PAO must be early 
in the insulin and vanadate cascades, which ultimately lead 
to activation of hexose-uptake and glucose metabolism. 
The evidence points to the blockage occurring at the level 
of tyrosine phosphorylation, particularly since antilipolysis 
was not affected and activation of hexose uptake and 
glucose metabolism by okadaic acid were not disturbed by 
PAO as well (Table 2, Fig. 3). Okadaic acid is a specific 
and potent inhibitor of PP2A and PP1 and its insulin 
effects (hexose uptake and glucose metabolism) as well as 
its anti-insulin effects (lipolysis) coincide with increased 
levels of PSer/PThr of key metabolic enzymes down- 
stream to tyrosine phosphorylation [21,22,35]. 
It should be noted at this point that the mechanism(s) by 
which insulin activates hexose transport (beyond the de- 
scriptive phenomena) is still obscure. Activation of hexose 
uptake by okadaic acid, bypassing the PAO blockage (Fig. 
3), is of significant interest. This is particularly valid in 
view of the dominant effect of PAO in arresting the 
activating effects of insulin, vanadate and pervanadate on 
this parameter (Fig. 2). Overall, this observation appears to 
suggest that hexose transport can be activated by an alter- 
native pathway, independent of endogenous tyrosine phos- 
phorylation, and that an event involving Ser/Thr phospho- 
rylation participates in the activation process (in prepara- 
tion). 
Attempts to identify the PAO-sensitive PTPase by di- 
rect inhibition of the enzyme with PAO were unsuccessful, 
suggesting that this PTPase comprises a minute fraction of 
the total adipocytic PTPase activity (Fig. 4). We applied, 
therefore, fractionation procedures and the PAO-dependent 
CytPTK-activating assay [7,9], and we were able to con- 
clude that the PAO-sensitive PTPase is exclusively associ- 
ated with the plasma membrane fraction (Fig. 5). The 
vanadate sensitive PTPases are distributed in the plasma 
membrane and in the supernatant compartments at a ratio 
of about 4 to 1. Moreover, extraction of the plasma 
membrane with Triton X-100 does not appear to reduce 
the activity of the vanadate sensitive PTPases whereas the 
PAO sensitive PTPase was inactivated indicating a clear 
qualitative difference between the various PTPases. It 
should be noted at this point that all the experiments 
summarized in Fig. 5 were performed with freshly pre- 
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pared adipocytes in order to eliminate the possible inacti- 
vation of the PAO-sensitive PTPase by freezing and thaw- 
ing. 
Next, we identified several proteins which were signifi- 
cantly phosphorylated in the supernatant of PAO but not in 
vanadate-treated adipocytes (Fig. 6). Thus, inhibition of 
the PAO sensitive PTPase appear to correlate with in- 
creased tyrosine phosphorylation f as yet unidentified 33, 
39, 43, 53 and 55 kDa supernatant proteins. These 
phosphorylated proteins may be markers, or a cause for the 
early blockage in the expression of insulin-like biore- 
sponses. It should be mentioned at this point that we have 
previously observed the appearance of a 43 kDa phospho- 
tyrosine-containing protein in cells treated with okadaic 
acid that became refractory to the modulating effects of 
vanadate and insulin [22]. 
Finally, it is interesting to note that unlike with the 
observations made by Lane's laboratory on 3T3-L1 
adipocytes and our observation made with the primary rat 
adipocytes, not every insulin-responsive c ll-type, under- 
goes desensitization by PAO. Balloti, Van Obberghen and 
colleagues found that PAO stimulates rather than inhibit 
glucose uptake in NIH3T3-mouse fibroblasts [36]. Thus, in 
the latter cell-line, PAO appears to be 'the vanadate' of the 
primary rat adipose cell. It is of interest to determine 
whether the NIH3T3 mouse fibroblast contains the cytoso- 
lic proteins that undergoes tyrosine phosphorylation i
PAO treated adipocytes. This and other issues which have 
emerged here are under study. 
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